Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Larotaxel in metastatic breast cancer
NCT00081796Phase 3Completed
- Sponsor
- Sanofi
- Start
- Apr 2004
- Primary completion
- Sep 2006
- Modality
- Small Molecules
- Countries
- 26
01
Overview
Phase 3, randomised, open-label trial of larotaxel in breast cancer (2 arms), sponsored by Sanofi. Primary endpoint: Time to tumor progression. Started Apr 2004; status: completed.
02
Drugs
larotaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00081796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00081796.